These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37751168)

  • 1. Prospective inter- and intra-tracer repeatability analysis of radiomics features in [
    Kendrick J; Francis RJ; Hassan GM; Rowshanfarzad P; Ong JSL; Jeraj R; Barry N; Hagan T; Ebert MA
    Br J Radiol; 2023 Dec; 96(1152):20221178. PubMed ID: 37751168
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Draulans C; Pos F; Smeenk RJ; Kerkmeijer L; Vogel WV; Nagarajah J; Janssen M; Mai C; Heijmink S; van der Leest M; Zámecnik P; Oyen R; Isebaert S; Maes F; Joniau S; Kunze-Busch M; De Roover R; Defraene G; van der Heide UA; Goffin K; Haustermans K
    Pract Radiat Oncol; 2021; 11(3):202-211. PubMed ID: 33941347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of
    Seifert R; Sandach P; Kersting D; Fendler WP; Hadaschik B; Herrmann K; Sunderland JJ; Pollard JH
    J Nucl Med; 2022 May; 63(5):746-753. PubMed ID: 34446454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Test-Retest Measurement of
    Pollard JH; Raman C; Zakharia Y; Tracy CR; Nepple KG; Ginader T; Breheny P; Sunderland JJ
    J Nucl Med; 2020 Aug; 61(8):1145-1152. PubMed ID: 31806776
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P
    Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeatability of Quantitative
    Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
    BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of repeatability of radiomic features derived from PET scans: Results from a
    Werner RA; Habacha B; Lütje S; Bundschuh L; Kosmala A; Essler M; Derlin T; Higuchi T; Lapa C; Buck AK; Pienta KJ; Lodge MA; Eisenberger MA; Markowski MC; Pomper MG; Gorin MA; Frey EC; Rowe SP; Bundschuh RA
    Prostate; 2023 May; 83(6):547-554. PubMed ID: 36632656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with
    Werner RA; Habacha B; Lütje S; Bundschuh L; Higuchi T; Hartrampf P; Serfling SE; Derlin T; Lapa C; Buck AK; Essler M; Pienta KJ; Eisenberger MA; Markowski MC; Shinehouse L; AbdAllah R; Salavati A; Lodge MA; Pomper MG; Gorin MA; Bundschuh RA; Rowe SP
    Mol Imaging; 2022; 2022():7056983. PubMed ID: 35283693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards improved diagnosis: radiomics and quantitative biomarkers in 18 F-PSMA-1007 and 18 F-fluorocholine PET/CT for prostate cancer recurrence.
    Panagiotidis E; Andreou S; Paschali A; Angeioplasti K; Vlontzou E; Kalathas T; Pipintakou A; Fothiadaki A; Makridou A; Chatzimarkou M; Papanastasiou E; Datseris I; Chatzipavlidou V
    Nucl Med Commun; 2024 Sep; 45(9):796-803. PubMed ID: 38832429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [
    Papp L; Spielvogel CP; Grubmüller B; Grahovac M; Krajnc D; Ecsedi B; Sareshgi RAM; Mohamad D; Hamboeck M; Rausch I; Mitterhauser M; Wadsak W; Haug AR; Kenner L; Mazal P; Susani M; Hartenbach S; Baltzer P; Helbich TH; Kramer G; Shariat SF; Beyer T; Hartenbach M; Hacker M
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1795-1805. PubMed ID: 33341915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on
    Yi Z; Hu S; Lin X; Zou Q; Zou M; Zhang Z; Xu L; Jiang N; Zhang Y
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1523-1534. PubMed ID: 34845536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer.
    Al Jalali V; Wasinger G; Rasul S; Grubmüller B; Wulkersdorfer B; Balber T; Mitterhauser M; Simon J; Hacker M; Shariat S; Egger G; Zeitlinger M
    J Nucl Med; 2023 Jun; 64(6):863-868. PubMed ID: 36657982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproducibility and Repeatability of Semiquantitative
    Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
    J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
    [No Abstract]   [Full Text] [Related]  

  • 16. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
    Lin C; Bradshaw T; Perk T; Harmon S; Eickhoff J; Jallow N; Choyke PL; Dahut WL; Larson S; Humm JL; Perlman S; Apolo AB; Morris MJ; Liu G; Jeraj R
    J Nucl Med; 2016 Dec; 57(12):1872-1879. PubMed ID: 27445292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
    Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
    Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthy Tissue Uptake of
    Jansen BHE; Kramer GM; Cysouw MCF; Yaqub MM; de Keizer B; Lavalaye J; Booij J; Vargas HA; Morris MJ; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2019 Aug; 60(8):1111-1117. PubMed ID: 30630941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.